As obesity and related metabolic disorders continue to rise, nonalcoholic steatohepatitis (NASH) has become the second most common cause of liver transplantation, yet no NASH-specific therapy has been approved. Animal models continue to play a key role in helping develop treatment options and revealing new information about its pathogenesis.
Download our insightful mini paper to understand how to:
- Induce obesity, metabolic syndrome, and mild NASH
- Induce hepatic features of severe NASH - without inducing metabolic symptoms such as obesity and insulin resistance
- Understand the key considerations when choosing a rodent diet
